Vaxcyte, Inc.
PCVX
Rankning i aktier
#2080
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Aktiekurs
$64.29
Senast synkroniserad: 2026-10-19
Marknadsvärde
$9.86B
Förändring (1 dag)
1.05%
Förändring (1 år)
49.86%
Land
US
Handel Vaxcyte, Inc. (PCVX)
Kategori
Healthcare
Antal utestående aktier för Vaxcyte, Inc. (PCVX)
Antal utestående aktier per June 2026: 144.49M
Enligt de senaste finansiella rapporterna och aktiekursen för Vaxcyte, Inc. är det aktuella antalet utestående aktier 144.49M. I slutet av December 2023 hade företaget 97.16M utestående aktier. Antalet utestående aktier påverkas vanligtvis av aktiesplit och återköp av aktier.
Historik över utestående aktier för Vaxcyte, Inc. (PCVX) från 2017 till 2026
Utestående aktier vid slutet av varje år
| År | Utestående aktier | Ändra |
|---|---|---|
| 2026 (TTM) | 144.49M | 18.44% |
| 2024 | 122.00M | 25.57% |
| 2023 | 97.16M | 49.75% |
| 2022 | 64.88M | 24.95% |
| 2021 | 51.92M | 75.74% |
| 2020 | 29.55M | 678.52% |
| 2019 | 3.80M | 4.57% |
| 2018 | 3.63M | 1.80% |
| 2017 | 3.57M | 0.00% |
Utestående aktier för liknande företag eller konkurrenter
| Företag | Utestående aktier | Skillnad | Land |
|---|---|---|---|
| 253.90M | 75.72% |
US
|
|
| 396.00M | 174.06% |
US
|
|
| 478.91M | 231.44% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -56.96% |
NL
|
